Lipoproteinapherese

Volker J. J. Schettler

doi:10.1055/a-1076-4419

Dialyse aktuell, Table of Contents

Dialyse aktuell 2020; 24(04): 163-168
DOI: 10.1055/a-1076-4419

Schwerpunkt

Nephrologie

Lipoproteinapherese

Wie ist der Stand im Jahr 2020?

Volker J. J. Schettler

¹Nephrologisches Zentrum Göttingen GbR, Göttingen

› Author Affiliations

Abstract

ZUSAMMENFASSUNG

Die Indikation zur Lipoproteinapheresetherapie bleibt auch unter Berücksichtigung neuer lipidsenkender Medikamente und Leitlinien in der Behandlung von Dyslipidämien unverändert bestehen. Diese lipidsenkende Therapieform führt nicht nur zur Absenkung von LDL-C und Lp(a), sondern wirkt zusätzlich antiinflammatorisch, antiatherogen und antithrombogen.

Full Text

References

Literatur
1 Brown MS, Kovanen PT, Goldstein JL. Regulation of plasma cholesterol by lipoprotein receptors. Science 1981; 212: 628-635 doi:10.1126/science.6261329
2 Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301: 2331-2339 doi:10.1001/jama.2009.801
3 Julius U. History of lipidology and lipoprotein apheresis. Atheroscler Suppl 2017; 30: 1-8 doi:10.1016/j.atherosclerosissup.2017.05.034
4 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4 S) Lancet. 1994; 344: 1383-1389
5 Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. Nat Rev Cardiol 2018; 15: 757-769
6 Mabuchi H, Koizumi J, Shimizu M. et al Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 1998; 82: 1489-1495 doi:10.1016/s0002-9149(98)00692-4
7 Schettler V, de Groot K, Fassbender C. et al Standard der Therapeutischen Apherese 2019 der Deutschen Gesellschaft für Nephrologie e. V. in Zusammenarbeit mit der Gesellschaft für pädiatrische Nephrologie e. V. 29.03.2019. Im Internet https://www.dgfn.eu/apherese-standard.html Stand: 30.03.2020
8 Schettler VJ, Ringel J, Jacob S. et al [Therapeutic algorithm for lipoprotein apheresis and PCSK9 inhibition for severe hypercholesterolemia or isolated lipoprotein(a) hyperlipoproteinemia]. Internist 2016; 57: 511-516 doi:10.1007/s00108-016-0043-9
9 Sabatine MS, Giugliano RP, Keech AC. et al Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376: 1713-1722 doi:10.1056/NEJMoa1615664
10 Schwartz GG, Steg PG, Szarek M. et al Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 2018; 379: 2097-2107 doi:10.1056/NEJMoa1801174
11 Dimmitt SB, Stampfer HG, Martin JH, Warren JB. Clinical benefits of evolocumab appear less than hoped. Lancet 2018; 391: 933-934 doi:10.1016/S0140-6736(18)30530-0
12 Moriarty PM, Parhofer KG, Babirak SP. et al Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J 2016; 37: 3588-3595 doi:10.1093/eurheartj/ehw388
13 Torres E, Goicoechea M, Hernandez A. et al Efficacy of Evolocumab vs low-density lipoprotein cholesterol apheresis in patients with familial hypercholesterolemia and high cardiovascular risk (EVOLAFER01). J Clin Apher 2020; 35: 9-17
14 Mach F, Baigent C, Catapano AL. et al ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111-188 doi:10.1093/eurheartj/ehz455
15 Spitthover R, Roseler T, Julius U. et al Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis. J Clin Apher 2019; 34: 423-433 doi:10.1002/jca.21695
16 Shapiro MD, Minnier J, Tavori H. et al Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab. J Am Heart Assoc 2019; 8: e010932 doi:10.1161/JAHA.118.010932
17 O’Donoghue ML, Fazio S, Giugliano RP. et al Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation 2019; 139: 1483-1492 doi:10.1161/CIRCULATIONAHA.118.037184
18 Cannon CP, Blazing MA, Giugliano RP. et al Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372: 2387-2397 doi:10.1056/NEJMoa1410489
19 Burgess S, Ference BA, Staley JR. et al Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. JAMA Cardiol 2018; 3: 619-627 doi:10.1001/jamacardio.2018.1470
20 Emerging Risk Factors C, Erqou S, Kaptoge S. et al Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 412-423 doi:10.1001/jama.2009.1063
21 Schettler VJJ, Neumann CL, Peter C. et al Current insights into the German Lipoprotein Apheresis Registry (GLAR) – Almost 5 years on. Atheroscler Suppl 2017; 30: 50-55 doi:10.1016/j.atherosclerosissup.2017.05.006
22 Deutsches Lipidapherese-Register Jahresbericht. 2018
23 Khan TZ, Hsu LY, Arai AE. et al Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial. Eur Heart J 2017; 38: 1561-1569 doi:10.1093/eurheartj/ehx178
24 Khan TZ, Gorog DA, Arachchillage DJ. et al Impact of lipoprotein apheresis on thrombotic parameters in patients with refractory angina and raised lipoprotein(a): Findings from a randomized controlled cross-over trial. J Clin Lipidol 2019; 13: 788-796 doi:10.1016/j.jacl.2019.06.009
25 Mellwig KP, van Buuren F, Schmidt HK. et al Improved coronary vasodilatatory capacity by H. E. L. P. apheresis: comparing initial and chronic treatment. Ther Apher Dial 2006; 10: 510-517 doi:10.1111/j.1744-9987.2006.00441.x
26 Wu MD, Moccetti F, Brown E. et al Lipoprotein Apheresis Acutely Reverses Coronary Microvascular Dysfunction in Patients With Severe Hypercholesterolemia. JACC Cardiovasc Imaging 2019; 12: 1430-1440 doi:10.1016/j.jcmg.2018.05.001
27 Sinzinger H, Steiner S, Derfler K. Pleiotropic effects of regular lipoprotein-apheresis. Atheroscler Suppl 2017; 30: 122-127 doi:10.1016/j.atherosclerosissup.2017.05.032
28 Wieland E, Schettler V, Armstrong VW. Highly effective reduction of C-reactive protein in patients with coronary heart disease by extracorporeal low density lipoprotein apheresis. Atherosclerosis 2002; 162: 187-191 doi:10.1016/s0021-9150(01)00698-0
29 Stefanutti C, Mazza F, Pasqualetti D. et al Lipoprotein apheresis downregulates IL-1alpha, IL-6 and TNF-alpha mRNA expression in severe dyslipidaemia. Atheroscler Suppl 2017; 30: 200-208 doi:10.1016/j.atherosclerosissup.2017.05.028
30 Aday AW, Ridker PM. Targeting Residual Inflammatory Risk: A Shifting Paradigm for Atherosclerotic Disease. Front Cardiovasc Med 2019; 6: 16 doi:10.3389/fcvm.2019.00016
31 Schettler VJJ, Neumann CL, Peter C. et al Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels. Clin Res Cardiol Suppl 2019; 14: 33-38 doi:10.1007/s11789-019-00094-4